About the Company
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CRVS News
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...
CRVS Apr 2024 4.000 put
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage ...
The Resilience of Monoclonal Antibodies and their Makers
The road to developing monoclonal antibodies for effectively targeting cancer was paved with tenacity, passion, and strokes ...
Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Ionis Pharmaceuticals (IONS) and Fusion Pharmaceuticals (FUSN)
Kalia covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Inspire Medical Systems ... focusing on stocks such as Perspective Therapeutics, Corvus Pharmaceuticals, ...
Earnings week ahead: FedEx, Nike, XPeng, Tencent, General Mills and more
StoneCo (STNE), a provider of financial technology and software solutions, is scheduled to report its Q4 earnings after ...
SmallCapVoice.com Inc. (“SCV”) to Host First Annual Safety Summit featuring Up-and-Coming Public Companies
Current Company Lineup (subject to change): Knightscope (Nasdaq: KSCP) builds cutting-edge technologies to improve public safety, and our long-term ambition is to make the United States of America the ...
Loading the latest forecasts...